Business Model Breakdown
How Omada Health Inc Makes Money
OMDA
Market Cap
$1.1B
Profit Margin
-2.2%
The Short Version
Omada Health is a digital health company that offers virtual care and chronic condition management programs, focusing on conditions like diabetes, hypertension, and behavioral health. It partners with large employers, health plans, and pharmacy benefit managers (PBMs) to provide its evidence-based programs to their members, aiming to improve health outcomes and reduce healthcare costs through continuous 'virtual between-visit care.' The company provides digital tools, health coaching, and connected devices to help individuals manage their health.
Where the Revenue Comes From
Subscription-based fees from employers, health plans, and PBMs for access to its digital health programs and services (~100% of revenue).
Who buys: Primarily large employers, health insurance plans, and pharmacy benefit managers (PBMs), who then offer Omada Health's services to their eligible employees or members.
Why It Works (Competitive Advantages)
- ✔Strategic PBM Partnerships (Access to Optum Rx, Lilly Employer Connect provides significant distribution and patient reach).
- ✔Integrated Prescribing Capabilities (Enhances patient engagement and expands the scope of virtual care delivery).
- ✔Evidence-Based Programs (Focus on clinically validated outcomes for chronic condition management).
Economic Moat: Narrow (Switching Costs (Integrated within employer/health plan benefit structures, patient inertia once enrolled in chronic care programs)., Intangible Assets/IP (Proprietary technology platform, accumulated health data from a large user base, clinical validation of programs)., Network Effects (Partnerships with major PBMs create a significant network effect for patient acquisition and program scale).)
What Our Analysis Says
DVR Score as of June 12, 2026
Omada Health continues to demonstrate strong 10x potential, underpinned by its rapid revenue scaling and confirmed operating leverage in Q1 2026 with a reported revenue of $78.05M and narrowed EPS loss of ($0.05). The company's strategic vision is clear, focused on expanding its digital chronic care footprint through major PBM partnerships. While the company remains unprofitable and carries a high valuation (P/S ~13.6x), its substantial cash reserves (previously $211.8M) provide a strong runway. Recent insider selling (tax-related dispositions) introduces a minor headwind, but the overall trajectory, analyst sentiment, and upcoming catalysts (Q2 earnings, conference visibility) keep the investment thesis robust. The score reflects continued positive operational momentum since the last analysis.